tbuckley/cabot-search huggingface dataset:
Validation of a Spanish version of the Leicester cough questionnaire in adult patients with non-cystic fibrosis bronchiectasis
Authors: Gerard Muñoz, Casilda Olveira, Miguel Angel Martinez-Garcia, Rosa Giron, Javier de Gracia, Antonio Alvarez, Maria Buxó, Eva Polverino, Gladis Sabater, Montserrat Vendrell
Journal: European Respiratory Journal (2013)

Cough is a main symptom in bronchiectasis (BC). The Leicester Cough Questionnaire (LCQ) has been validated in adult patients with non-cystic fibrosis (CF)-BC. This study aimed to create and validate a Spanish version of the LCQ in adult patients with non-CF-BC participating in a prospective longitudinal multicentric study.  Methods:Validity was assessed by correlating the LCQ with the Saint George’s Respiratory Questionnaire (SGRQ) and clinical variables when stable. Reliability was assessed by recording changes in the LCQ score 15 days after the initial observations of the patients in stable state. Responsiveness was assessed by the change in LCQ scores between the first visit and the first exacerbation during the 6 months following enrolment.  Results:259 patients (mean age 58±18 years) in 6 different hospitals were included. Validity: The correlation between LCQ and SGRQ scores was -0.696. There were significant correlations with clinical variables (mean difference in the LCQ score >1.3, p  Conclusions:Like the English version, the Spanish version of the LCQ is able to discriminate disease severity, is responsive to change, and is reliable for use in non-CF-BC. It will also facilitate comparison with studies of English-speaking patients.  Study sponsored by PII Bronquiectasias, SEPAR.
Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results
Authors: S. F. Jones, H. A. Burris, H. Dumez, J. R. Infante, C. Fowst, P. Gerletti, H. Xu, J. Jakubczak, N. Mellaerts, P. Schöffski
Journal: Journal of Clinical Oncology (2008)

2517 Background: Aurora kinases are a family of kinases that play a crucial role in regulating segregation of chromosomes and have been linked to tumorigenesis. Aurora kinase A is commonly amplified in solid tumors and has been established as an oncogene. Aurora B is over-expressed in tumors and leads to defects in mitosis and increased invasiveness. PF-03814735 is a novel oral ATP-competitive, reversible inhibitor of Aurora A and B kinases with a broad spectrum of preclinical activity. Methods: This is an accelerated dose-escalation study to identify the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose, and to obtain proof-of-mechanism (by assessment of pH3 inhibition in tumor biopsies and FDG-PET) with PF-03814735 administered daily for 5 or 10 consecutive days in 3-week cycles. Results: Twenty patients received a median of 2 cycles (1–4) across 7 dose levels from 5 to 100 mg/day for 5 days. Tumor types included colorectal (5), breast (3), NSCLC (4), SCLC (2), bladder, melanoma, ovarian, renal, head and neck and cancer of unknown primary (1 each). The dose was doubled in single patient cohorts until treatment-related grade 2 diarrhea occurred in one patient at 40 mg/day. Afterwards, cohorts included 3–7 patients with 20–50% dose increments per cohort. In the first 16 patients, the most common treatment-related adverse events were mild to moderate diarrhea (50%), vomiting (25%), anorexia, fatigue, and nausea (19% each). Dose-limiting febrile neutropenia was observed in 2/7 patients treated at 100mg/day. No objective response has been reported. One ovarian cancer patient has received 4 cycles at 80 mg/day. One head and neck cancer patient has received 4 cycles at 100 mg/d and continues. Serum exposure of PF-03814735 (Cmax and AUC) increased in a dose-proportional manner at all dose levels. After a single dose, the total clearance of PF-03814735 is 1195±393 mL/hr and median terminal half-life is 19.1 hr. PK of PF-3814735 is linear. Conclusions: The MTD was defined as 80 mg/day for five days. This dose level is currently being expanded to obtain proof-of-mechanism data at the recommended phase II dose. Dose escalation on the 10-day treatment schedule is occurring simultaneously. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Pfizer Pfizer Pfizer Pfizer
Multi-center phase II study of irinotecan + 5-FU/<i>l-</i>LV (RPMI) chemotherapy for patients with metastasic colorectal cancer (OGSG0201)
Authors: H. Mishima, H. Ishida, S. Iwamoto, T. Morimoto, T. Kato, T. Tsujinaka, H. Furukawa
Journal: Journal of Clinical Oncology (2005)

3700 Background: To evaluate the toxicity and efficacy of combination chemotherapy with irinotecan plus 5-FU/l-LV (RPMI) in patients with metastatic colorectal cancer(MCC). Methods: Forty-five patients with MCC entered this multi-centered, community-based, phase II study conducted by the Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) (Proc ASCO 22; 299, 2004). All patients were treated with irinotecan (100mg/m2), 5-FU (500 mg/m2) and l-LV (250mg/m2) on day 1, 8 and 15. Cycles were repeated every 5 weeks. Patients received second line therapy based on institutional preferences. Results: With the median follow up of 16 months (1.6–27 months), the MST was 21.1 months and the one-year survival rate was 73.3%. The response rate was 26.7% (CR 1, PR 11, SD 28, PD 5). The median relative dose intensity was 83.3% for irinotecan and 5-FU respectively. Grade 3 or 4 toxities were anemia (8.9%), leukopenia (13.3%), neutropenia (33.3%), diarrhea (6.7%), nausea (4.4%), vomiting (2.2%) and anorexia (4.4%). 5-FU/CDDP and oral FU were the second line treatment, except one patient received oxaliplatin (FOLFOX4) and cetuximab (not yet authorized in Japan). Conclusions: Despite the RR was not high enough, the survival period was favorable (21.1 months). It is expected that irinotecan + 5-FU/l-LV (RPMI), followed by the treatment with oral FU, oxaliplatin and molecule-targeting drugs may achieve the prolonged survival of patients with MCC. No significant financial relationships to disclose.
Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study
Authors: Walter P Maksymowych, Maxime Dougados, Désirée van der Heijde, Joachim Sieper, Jürgen Braun, Gustavo Citera, Filip Van den Bosch, Isabelle Logeart, Joseph Wajdula, Heather Jones, Lisa Marshall, Randi Bonin, Ron Pedersen, Bonnie Vlahos, Sameer Kotak, Jack F Bukowski
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objective</h3> To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA). <h3>Methods</h3> Patients meeting Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA, but not modified New York radiographic criteria, received double-blind ETN 50 mg/week or placebo (PBO) for 12 weeks, then open-label ETN (ETN/ETN or PBO/ETN). Clinical, health, productivity, MRI and safety outcomes were assessed and the 48-week data are presented here. <h3>Results</h3> 208/225 patients (92%) entered the open-label phase at week 12 (ETN, n=102; PBO, n=106). The percentage of patients achieving ASAS40 increased from 33% to 52% between weeks 12 and 48 for ETN/ETN and from 15% to 53% for PBO/ETN (within-group p value &lt;0.001 for both). For ETN/ETN and PBO/ETN, the EuroQol 5 Dimensions utility score improved by 0.14 and 0.08, respectively, between baseline and week 12 and by 0.23 and 0.22 between baseline and week 48. Between weeks 12 and 48, MRI Spondyloarthritis Research Consortium of Canada sacroiliac joint (SIJ) scores decreased by −1.1 for ETN/ETN and by −3.0 for PBO/ETN, p&lt;0.001 for both. Decreases in MRI SIJ inflammation and C-reactive protein correlated with several clinical outcomes at weeks 12 and 48. <h3>Conclusions</h3> Patients with early active nr-axSpA demonstrated improvement from week 12 in clinical, health, productivity and MRI outcomes that was sustained to 48 weeks. <h3>Trial registration number</h3> NCT01258738.
Sensitization to Hyperthermia below 43° C Induced in Chinese Hamster Ovary Cells by Step-Down Heating2
Authors: Kurt J. Henle
Journal: JNCI Journal of the National Cancer Institute (1980)

Journal Article Sensitization to Hyperthermia below 43° C Induced in Chinese Hamster Ovary Cells by Step-Down Heating Get access Kurt J. Henle Kurt J. Henle Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 64, Issue 6, June 1980, Pages 1479–1483, https://doi.org/10.1093/jnci/64.6.1479 Published: 01 June 1980 Article history Received: 08 August 1979 Accepted: 02 December 1979 Published: 01 June 1980
BMA welcomes government’s U turn on Acas talks ahead of planned strike
Authors: Abi Rimmer
Journal: BMJ (2015)

The BMA has welcomed the government’s decision to enter conciliation talks in a bid to avert strike action by junior doctors. It said that, to defer industrial action on 1 December, the government must finally remove its threat of imposition.

In a letter to the BMA chair on Wednesday 25 November the health secretary, Jeremy Hunt, said that he was willing to enter conciliation talks with the association.

Mark Porter, BMA chair, said it was encouraging that Hunt had finally recognised that trust had broken down between junior doctors and the government. “We …
Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood–brain barrier in vitro and in vivo
Authors: Houmam Kafa, Julie Tzu-Wen Wang, Noelia Rubio, Rebecca Klippstein, Pedro M. Costa, Hatem A.F.M. Hassan, Jane K. Sosabowski, Sukhvinder S. Bansal, Jane E. Preston, N. Joan Abbott, Khuloud T. Al-Jamal
Journal: Journal of Controlled Release (2016)

Brain glioblastoma and neurodegenerative diseases are still largely untreated due to the inability of most drugs to cross the blood–brain barrier (BBB). Nanoparticles have emerged as promising tools for drug delivery applications to the brain; in particular carbon nanotubes (CNTs) that have shown an intrinsic ability to cross the BBB in vitro and in vivo. Angiopep-2 (ANG), a ligand for the low-density lipoprotein receptor-related protein-1 (LRP1), has also shown promising results as a targeting ligand for brain delivery using nanoparticles (NPs). Here, we investigate the ability of ANG-targeted chemically-functionalised multi-walled carbon nanotubes (f-MWNTs) to cross the BBB in vitro and in vivo. ANG was conjugated to wide and thin f-MWNTs creating w-MWNT-ANG and t-MWNT-ANG, respectively. All f-MWNTs were radiolabelled to facilitate quantitative analyses by γ-scintigraphy. ANG conjugation to f-MWNTs enhanced BBB transport of w- and t-MWNTs-ANG compared to their non-targeted equivalents using an in vitro co-cultured BBB model consisting of primary porcine brain endothelial cells (PBEC) and primary rat astrocytes. Additionally, following intravenous administration w-MWNTs-ANG showed significantly higher whole brain uptake than the non-targeted w-MWNT in vivo reaching ~ 2% injected dose per g of brain (%ID/g) within the first hour post-injection. Furthermore, using a syngeneic glioma model, w-MWNT-ANG showed enhanced uptake in glioma brain compared to normal brain at 24 h post-injection. t-MWNTs-ANG, on the other hand, showed higher brain accumulation than w-MWNTs. However, no significant differences were observed between t-MWNT and t-MWNT-ANG indicating the importance of f-MWNTs diameter towards their brain accumulation. The inherent brain accumulation ability of f-MWNTs coupled with improved brain-targeting by ANG favours the future clinical applications of f-MWNT-ANG to deliver active therapeutics for brain glioma therapy.
Abstract 3154: Interacton of Left Ventricular Geometry and Cardiovascular Hemodynamics in 57,307 Patients wth Preserved Ejection Fraction
Authors: Richard V Milani, Carl J Lavie
Journal: Circulation (2007)

We and others have demonstrated the prognostic impact of LV geometry on subsequent survival in patients with preserved ejection. The purpose of this investigation was to describe parameters of cardiovascular hemodynamics and energetics associated with normal and abnormal LV geometry, including concentric remodeling (CR), eccentric hypertrophy (EH), and concentric hypertrophy (CH) fraction in patients who were referred for routine echocardiographic evaluation. Measures were obtained using standard non-invasive methods previously reported. Survival was obtained by the National Death Index after a mean follow-up of 2.8 years. Conclusion: Changes in LV geometry are associated with significant abnormalities in cardiac and vascular hemodynamics and energetics that in general progress from CR to frank hypertrophy. Intervention directed towards modifying these parameters are needed in order to evaluate the potential for improving clinical outcomes.
Cisplatin(P)-including triplets versus P-free doublets in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC): SICOG 0101 randomized trial
Authors: P. Comella, S. Palmeri, G. De Cataldis, G. Filippelli, R. Cioffi, A. Farris, L. Maiorino, B. Massidda, M. Roselli, A. Gambardella
Journal: Journal of Clinical Oncology (2006)

7103 Background: We previously reported that triplets with P-gemcitabine (G) plus vinorelbine (V) (PGV) or paclitaxel (T) (PGT) prolonged the survival (S) of advanced NSCLC patients (pts) in comparison with P-based doublets (PG or PV). Aims of the present study were: (1) to compare (log-rank test) the S of P-based triplets vs P-free doublets, and (2) to compare (Fisher test) safety and response rate (RR) of T- and V-regimens. Methods: A 2x2 factorial design was adopted. Pts aged ≤ 70 years, with PS (ECOG) &lt; 2, inoperable stage IIIA, IIIB, or IV NSCLC were randomly treated with: GV = G 1,000 mg/m 2 + V 25 mg/m 2 on day (D) 1 and 8; GT = G 1,000 mg/m 2 + T 125 mg/m 2 on D 1 and 8; PGV = P 50 mg/m 2 on D 1 and 8 + GV; PGT = P 50 mg/m 2 on D 1 and 8 + GT. In all arms, cycles were repeated Q 3 weeks. Only responder pts after 3 cycles received further chemotherapy (CT). Thoracic RT was delivered after CT to pts with intra-thoracic disease. 330 events were required to have a 90% power to demonstrate (two-sided P &lt; 0.05) a 30% reduction of hazard of death. Results: From April 2001 to December 2005, 431 pts were recruited in the 4 arms. Characteristics in % were well balanced in P-based triplets and P-free doublets: males, 84/91; PS 0, 25/23; squamous cell carcinoma, 38/42; weight loss, 22/29; stage IV, 66/65; CNS metastases, 5/8; ≥ 2 metastatic sites, 29/30. So far, 411 pts were assessed for response: RR of triplets vs doublets was 88/204 (43%) vs 68/207 (33%) (P = 0.020), and of T-based vs V-based regimens was 40% vs 36% (P = 0.218). To date, 313 deaths were registered: median and 1-year S were 10.6 mo. and 41% for pts treated with triplets, and 10.4 mo. and 39% for pts treated with doublets (P = 0.786). Over initial 3 courses, occurrence of grade ≥ 3 toxicity (T vs V, % pts) was: neutropenia, 18% vs 30% (P &lt; 0.004); febrile neutropenia, 4% vs 7%; platelets, 7% vs 12% (P = 0.056); anemia, 5% vs 7%; vomiting, 1% vs 2%; diarrhea, 6% vs 3%; stomatitis, 3% vs 0.5%. Grade ≥ 2 neurotoxicity occurred in 1% of both groups. Conclusions: Activity was significantly higher with P-based triplets, but they did not affect the OS. T-based regimens were equally active and less toxic than V-based regimens. Therefore, the GT regimen may represent a new standard of care for advanced NSCLC pts. No significant financial relationships to disclose.
Salt and Sodium Intake in China
Authors: David B. Hipgrave, Suying Chang, Xiaowei Li, Yongning Wu
Journal: JAMA (2016)

Salt and Sodium Intake in ChinaNoncommunicable diseases are increasing globally, with major socioeconomic implic ations. 1 The World Health Organization 2 proposed 9 noncommunicable diseaserelated targets, including 30% reduction in salt/sodium intake to reduce risk of hypertension.In China, hypertension prevalence is rising 3 and salt intake is high (12 g/person/d). 4 However, this estimate derives from 2002, and China's dietary habits are changing.We compared salt and sodium consumption in China in 2000 with 2009-2012.Method | The National Centre for Food Safety Risk Assessment Ethics Committee approved China's total diet studies.All participating householders provided oral consent.Total diet studies include weighed food intake and laboratory analysis of prepared foods representing dietary intake, using a standardized design. 5 They are designed to assess food consumed and its biochemical content, accounting for losses during processing, preparation, and storage.By 2011, Table.Weighed Daily Salt Intake and Laboratory-Analyzed Sodium Intake of a Standard Person in 12 Provinces of China in 2000 and 2009-2011 and in 8 Additional Provinces in 2009-2012 Weighed Salt Intake, g c Yields a calculated sodium intake of 4.6 g/d in 2000, and 3.5 g/d in 2009-2011, based on the molecular mass of salt (58.4 g/mol) and atomic weight of sodium (23 g/mol).
Oral Contraceptive Use and Fibrocystic Breast Disease of Different Histologic Classifications&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: C C Hsieh, A W Crosson, A M Walker, E J Trapido, B MacMahon
Journal: JNCI Journal of the National Cancer Institute (1984)

The relationship between oral contraceptive (OC) use and occurrence of fibrocystic breast disease (FBD) of different histologic classifications was evaluated with data from a cohort study. Biopsy specimens from 232 women with FBD were classified into different atypia categories. In 96 matched pairs of OC users and nonusers, atypia scores were lower in users than in nonusers. Women without breast diseases (500 OC users and 500 nonusers) were sampled from the original cohort to form a two-stage “anamorphic” study with the 232 cases of FBD. The previously shown inverse association between OC use and FBD occurrence was present and increased with increased length of OC use. However, the “protective effect” of OC use did not vary for different histologic classifications of FBD. The findings from both paired and anamorphic analyses of the data are not consistent with the hypothesis that the use of OC is associated with decreased frequency only of FBD with minimal epithelial atypia.
Health Risk Behaviors Among Adolescents Who Do and Do Not Attend School-United States, 1992
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M. D. Anderson Cancer Center (MDACC) experience
Authors: A. J. Rodney, A. Siefker-Radtke, N. M. Tannir, S. Swisher, G. Walsh, R. E. Millikan, L. C. Pagliaro
Journal: Journal of Clinical Oncology (2006)

14538 Background: PMGCT are uncommon germ cell malignancies. Mediastinal nonseminomatous germ cell tumors (NSGCT) have a poor prognosis, whereas pure seminoma (Sem) has a good or intermediate prognosis irrespective of mediastinal presentation. Methods: We retrospectively identified 19 male pts with PMGCT seen at MDACC between October 1998 and September 2004 from a clinical database. Pts with resectable NSGCT were offered surgery upon plateau of their chemotherapy response. Prior to referral, 1 pt had primary surgical resection without preoperative (preop) chemotherapy. Results: There were 14 pts with NSGCT and 5 with good prognosis Sem. The median age was 29.5 (20–60). Seven pts with NSGCT had mixed or undifferentiated histology, and the remainder had pure yolk sac (5 pts) or choriocarcinoma (2 pts). The estimated median survival (Kaplan-Meier) for all patients (Sem + NSGCT) was 21 months. All pts with Sem were alive and disease-free at last follow-up (median 12 months, range 7–34). All pts with Sem received 4 courses of etoposide and cisplatin (EP); one also received bleomycin (BEP); one received radiotherapy consolidation; none received surgery. Of the pts with NSGCT, 9 (64%) have died, including 1 who refused surgery. Five pts with NSGCT were alive at last follow-up and 3 (21%) were disease-free (15+, 27+ and 35+ months). Four pts with NSGCT (29%) reached beyond 2 years survival (27+, 28, 35+, and 63+ months) including 3 with lung metastases and one with elevated preop alpha-fetoprotein (28,022 ng/ml). Each of these pts received 6–10 courses of multiple-regimen preop chemotherapy, and 2 received initially 4 courses of BEP without marker normalization. Conclusions: Mediastinal Sem treated with 4 courses EP had an excellent outcome without surgery. Pts with mediastinal NSGCT had a 64% mortality rate despite aggressive treatment. Several pts with mediastinal NSGCT did achieve long-term survival following aggressive chemotherapy and surgery, even with lung metastases and failure to normalize markers. A phase III trial of BEP versus dose-dense chemotherapy for poor-prognosis NSGCT is now in progress at MDACC. No significant financial relationships to disclose.
Changes in Sexual Behavior and Condom Use Associated with a Risk-Reduction Program—Denver
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal